Table 1 Demographics characteristics, HIV disease status and laboratory results

Receiving darunavir/ritonavir. N (%)

19 (26)

27 (37.5)

0.124

Receiving abacavir. N (%)

12 (16.2)

NA

Receiving tenofovir. N (%)

60 (81.0)

NA

Receiving zidovudine. N (%)

2 (2.7)

NA

Receiving lamivudine. N (%)

20 (27.0)

NA

Receiving emtricitabine. N (%)

54 (72.9)

NA

Male. N (%)

52 (70.3)

52 (72.2)

0.794

Age. Median (IQR)

44 (40–48)

47 (44–51)

0.002

Prior medical disease*. N (%)

27 (36.5)

36 (50)

0.099

Hepatitis C active. N (%)

18 (24.3)

14 (19.4)

0.932

AIDS. N (%)

47 (63.5)

44 (61.1)

0.764

CD4 nadir (cells/μL). Median (IQR)

141 (47–244)

172 (53–268)

0.376

Current CD4 (cells/μL). Median (IQR)

576 (417–805)

623 (457–834)

0.225

Years virologically suppressed.

   Median (IQR)

4.7 (2.9–8.9)

7.1 (4.5–8.9)

0.019

   Monotherapy

NA

2.6 (1.9–3.9)

Patients with a single blip **. N (%)

8 (10.8)

4 (5.5)

0.249

Detectable HIV RNA (Ultrasensitive assay). N (%)

33 (44.6)

28 (38.9)

0.484

HIV RNA 20–49 copies/ml. N (%)

12 (16.2)

5 (6.9)

0.081

Triglycerides (mg/dL). Median (IQR)

149 (111–196)

189 (137–248)

0.007

LDL Cholesterol. Median (IQR)

125 (107–153)

132 (110–156)

0.161

Total Cholesterol/HDL ratio. Median (IQR)

3.8 (3.3–4.7)

4.6 (3.7–5.6)

0.003

Total Cholesterol/LDL ratio. Median (IQR)

1.6 (1.5–1.8)

1.6 (1.5–1.8)

0.668

Receiving statins. N (%)

17 (25.4)

16 (24)

0.484

HOMA index. Median (IQR)

1.7 (1.0–2.7)

2.1 (1.3–3.4)

0.105

CRP level(mg/L).Median (IQR)

0.9 (0–2.4)

1.3 (0–2.8)

0.478

CRP ≥5 mg/L. N (%)

5 (6.8)

10 (14.5)

0.139

IL-6 (pg/ml).

   Median(IQR)

1.9 (1.2–3.4)

1.7 (1.3–3)

0.504

   IL-6 ≥ 3 pg/ml. N (%)

17 (23)

18 (25)

0.774

Fibrinogen (mg/dl). Median (IQR)

386 (351–452)

398 (362–447)

0.372

D-dimer (ng/ml). Median (IQR)

131 (99–214)

137 (99–234)

0.769